
On Thursday, Lundbeck and partner Otsuk received the green light from the US Food and Drug Administration (FDA) to expand the use of the schizophrenia treatment to include patients aged 13 to 17 years, reports a shared press release.
Up to now, Rexulti has only been approved to treat adults with schizophrenia and as an adjunctive treatment of major depressive disorder. However, the younger segment is particularly important when it comes to schizophrenia, as the disorder often starts developing in adolescence.
Already a subscriber? Log in.
Read the whole article
Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
- Access all locked articles
- Receive our daily newsletters
- Access our app